The company intends to introduce Synvisc in Japan by the end of this year.
Further, Genzyme has provided exclusive commercialisation rights to Teijin Pharma for Synvisc in Japan, under an agreement signed between the companies.
Teijin Pharma president Osamu Nishikawa said that doctors and patients will be pleased to have a new product available that provides OA knee pain relief with just three injections rather than multiple injection products which are currently on the market.
“We look forward to utilising our marketing and sales experience in the orthopaedics space to offer physicians and patients this therapeutic option,” Nishikawa said.